The AI in Medicine and Nursing Symposium, hosted by the UAB Heersink School of Medicine, UAB Medicine, UAB School of Health Professions, UAB School of Nursing, and Maastricht University Faculty of Science and Engineering, concluded successfully, bringing together leading experts, researchers, and industry representatives to explore the transformative potential of artificial intelligence (AI) in health care.

Marnix E. Heersink Institute for Biomedical Innovation (Innovation Institute) leadership regularly takes part in various events regarding artificial intelligence (AI) in medicine and health care, offering their expertise and professional insight. This fall, three of the institute’s leaders participated in a one-day program titled “A Primer for AI in Healthcare,” co-offered by the UAB School of Health Profession’s Department of Health Services Administration Center for Healthcare Management & Leadership.

The Marnix E. Heersink Institute for Biomedical Innovation hosted a Grand Rounds presentation titled "How an Innovation System Uncovered Breakthrough Solutions for CAUTI and AKI" with speaker Todd Dunn, an experienced transformation and innovation executive, on Tuesday, Oct 3.

Udbhav Ram, an international scholar from McMaster University, recently joined Carlos E. Cardenas, Ph.D., in his lab to study and research and serve as an undergraduate ambassador.

This live biotherapeutic product, tested in mouse models, shows promise in addressing common pathways of lung disease progression.

The Marnix E. Heersink Institute for Biomedical Innovation hosted a Grand Rounds presentation titled "Innovating the Future of Healthcare Design" with speakers Tushar Gupta, Mark Vaughan, and Chris Ressler, renowned leaders in healthcare architecture and design, on Tuesday, July 16.

University of Alabama at Birmingham (UAB) faculty members recently participated in the AI in Medicine and Healthcare Symposium at Maastricht University, which brought together experts and stakeholders to discuss the role of artificial intelligence (AI) in transforming health care.

UAB now enrolling students in the Master of Science degree in artificial intelligence in medicine.

UAB recently hosted a VR/AR Association meeting that brought together innovators and experts from across the country to explore the application of virtual reality (VR) and augmented reality (AR) in solving real-world challenges.

The Marnix E. Heersink Institute for Biomedical Innovation offers an AI in Medicine Graduate Certificate to meet the growing impact of artificial intelligence in academic medicine. Stevan Fairburn, a UAB MS2 student currently enrolled in the program, met with the Heersink communications team to shed some light on the certificate program and its curriculum. 

The Marnix E. Heersink Institute for Biomedical Innovation held a Grand Rounds presentation with speaker Christy Harris Lemak, PhD., Professor in the Department of Health Services Administration in the School of Health Professions at the University of Alabama at Birmingham, on Tuesday, April 2. 

The United States Association for Small Business and Entrepreneurship (USASBE) recently held its annual conference in Birmingham, Alabama, from Jan. 9-14, 2024. Hosted by the University of Alabama at Birmingham (UAB) J. Frank Barefield, Jr. Entrepreneurship Program, the event, titled USASBE 2024: Forging the Future Together, brought together educators, innovators, and entrepreneurs from across the country and featured many team members from the UAB Heersink School of Medicine and UAB Medicine.

Experts at ATTIS 2023 shared reports from the front lines, including how they are using ChatGPT in their labs, the need for regulation and why this is a “tremendous time” for health care.

The grant validates the science of Alveolus Bio, and the funds will support development of first-of-its-kind inhaled biotherapeutics to treat chronic lung diseases.

The event will explore a future of health care that “is going to be anchored in the metaverse” and be the first such symposium to be held both live and in the metaverse itself, according to Rubin Pillay, M.D., Ph.D., executive director of the Marnix E. Heersink Institute for Biomedical Innovation.

Experimental neonatal chronic lung disease is marked by a redox imbalance that damages the lungs, and that damage can be ameliorated using a live biotherapeutic mixture of three Lactobacillus species.